GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2011

miR-34a Found to Suppress Prostate Cancer Stem Cells

  • A group of researchers have demonstrated that miR-34a inhibits prostate cancer tumor-initiating cells by suppressing CD44, a cell surface protein prevalent on cancer cells. The research was conducted by scientists at the University of Texas MD Anderson Cancer Center and Mirna Therapeutics. miR-34a is one of eight miRNAs in preclinical development by the company.

    “Our findings are the first to profile a microRNA expression pattern in prostate cancer stem cells and also establish a strong rationale for developing the microRNA miR-34a as a new treatment option for prostate cancer,” says senior author, Dean Tang, Ph.D., professor in MD Anderson's department of molecular carcinogenesis.

    The paper, “The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44,” is published in Nature Medicine.

    The study demonstrated that miR-34a was under-expressed in CD44+ prostate cancer cells purified from xenograft and primary tumors. Enforced expression of miR-34a in bulk or purified CD44+ prostate cancer cells inhibited clonogenic expansion, tumor regeneration, and metastasis.

    When miR-34a antagomirs were expressed in CD44- cancer cells, tumor development and metastasis was promoted. Also, when miR-34a was systemically delivered, it inhibited prostate cancer metastasis and extended the survival of tumor-bearing mice. The researchers concluded that miR-34a is a key negative regulator of CD44+ prostate cancer cells.

    “CD44 has long been linked to promotion of tumor development and, especially, to cancer metastasis,” says Dr. Tang. “Many cancer stem cells over-express this surface adhesion molecule. Another significant finding from our study is identifying CD44 itself as a direct and functional target of miR-34a.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?